| Epidemiology from Literature | | Cohort | Year | Country | Test | Subjects | Positive (%) | Bibliography | | 1.1 - Asymptomatic | 2003 | Singapore | IgE | 105 | 12.400 | | | 1.1 - Asymptomatic | 2014 | Spain | IgE | 50 | 0.000 | 20140625, Armentia A
| | 1.10 - Any allergy symptom, Diagnosed | 2010 | Belgium | IgE | 86 | 15.110 | 20101214, Gadisseur R
| | 1.10 - Any allergy symptom, Diagnosed | 2014 | Brazil | IgE | 49 | 71.400 | 20141118, Santiago HD
| | 1.10 - Any allergy symptom, Diagnosed | 2014 | Brazil | IgE | 37 | 32.400 | 20141118, Santiago HD
| | 1.10 - Any allergy symptom, Diagnosed | 2010 | Italy | IgE | 16408 | 24.630 | 20100301, Scala E
| | 1.11 - Esophagitis, Diagnosed | 2013 | Netherlands | IgE | 76 | 28.900 | 20131020, van Rhijn BD
| | 1.11 - Esophagitis, Diagnosed | 2014 | Spain | IgE | 67 | 8.900 | 20140625, Armentia A
| | 1.11 - Esophagitis, Diagnosed | 2013 | Switzerland | IgE | 35 | 22.860 | 20130605, Simon D
| | 1.2.1 - Asthma, Diagnosed (Adults) | 2003 | Malaysia | IgE | 94 | 39.000 | | | 1.2.1 - Asthma, Diagnosed (Adults) | 2012 | Sweden | IgE | 96 | 2.080 | 20120528, Patelis A
| | 1.2.2 - Asthma, Diagnosed (Children) | 2003 | Malaysia | IgE | 49 | 57.000 | | | 1.3 - Rhinitis, Diagnosed | 2003 | Singapore | IgE | 124 | 42.700 | | | 1.4 - Respiratory Symptoms, Diagnosed | 2014 | Austria | IgE | 42 | 76.000 | 20140707, Banerjee S
| | 1.4 - Respiratory Symptoms, Diagnosed | 2005 | Germany | IgE | 132 | 29.500 | | | 1.4 - Respiratory Symptoms, Diagnosed | 1994 | Taiwan | SPT | 45 | 78.000 | | | 1.4 - Respiratory Symptoms, Diagnosed | 2002 | Thailand | SPT | 95 | 27.400 | | | 1.4 - Respiratory Symptoms, Diagnosed | 2002 | Thailand | SPT | 85 | 30.590 | 2002, Trakultivakorn M
| | 1.5 - Atopic Dermatitis, Diagnosed | 2014 | Austria | IgE | 5 | 100.000 | 20140707, Banerjee S
| | 1.5 - Atopic Dermatitis, Diagnosed | 2014 | Germany | IgE | 100 | 82.000 | 20140707, Banerjee S
| | 1.5 - Atopic Dermatitis, Diagnosed | 2013 | Germany | IgE | 140 | 38.570 | 20130111, Ott H
| | 1.5 - Atopic Dermatitis, Diagnosed | 2009 | Germany | IgE | 20 | 60.000 | 20091005, Ott H
| | 1.5 - Atopic Dermatitis, Diagnosed | 2005 | Germany | IgE | 113 | 23.000 | | | 1.5 - Atopic Dermatitis, Diagnosed | 2014 | Korea, Republic of | IgE | 25 | 40.000 | 20140821, Choi JS
| | 1.9 - Pollen Allergy | 2014 | Spain | IgE | 50 | 2.000 | 20140625, Armentia A
| | 10.1 - Normal Control | 2012 | Belgium | IgE | 27 | 7.410 | 20110223, De Knop KJ
| | 10.1 - Normal Control | 2009 | Belgium | IgE | 26 | 0.000 | 20091121, Ebo DG
| | 3.2.1 - Source Sensitized (IgE) | 2002 | Brazil | IgE | 149 | 76.500 | | | 3.2.1 - Source Sensitized (IgE) | 2010 | United States | IgE | 21 | 95.230 | 20100315, Mueller GA
| | 4.1.4 - Heterologous Source Sensitized (Symptoms, IgE) | 2012 | Austria | IgE | 54 | 20.400 | 20120310, Twaroch TE
| | 4.1.4 - Heterologous Source Sensitized (Symptoms, IgE) | 2009 | Belgium | IgE | 22 | 31.820 | 20091121, Ebo DG
| | 4.1.4 - Heterologous Source Sensitized (Symptoms, IgE) | 2012 | Italy | IgE | 26 | 9.300 | 20120310, Twaroch TE
| | 4.1.4 - Heterologous Source Sensitized (Symptoms, IgE) | 2008 | Sweden | IgE | 31 | 3.000 | 20081121, Weghofer M
| | 4.1.5 - Heterologous Source Sensitized (IgE) | 2009 | Belgium | IgE | 20 | 30.000 | 20091121, Ebo DG
| | 4.1.7 - Heterologous Source Sensitized (Symptoms, SPT, IgE) | 2009 | Belgium | IgE | 37 | 45.940 | 20090826, Ebo DG
| | 5.1.1 - Source Exposed (Symptoms) | 2013 | Germany | IgE | 98 | 76.530 | 20130501, Becker S
| | 5.1.1 - Source Exposed (Symptoms) | 2005 | New Zealand | IgE | 199 | 30.600 | | | 5.2.1 - Source Exposed (Symptoms, SPT) | 2004 | Australia / Austria | IgE | 78 | 91.000 | | | 5.2.1 - Source Exposed (Symptoms, SPT) | 2011 | China | IgE | 100 | 94.000 | 20111214, Zheng YW
| | 5.2.1 - Source Exposed (Symptoms, SPT) | 2014 | Spain | IgE | 48 | 77.800 | 20141122, Morales M
| | 5.2.1 - Source Exposed (Symptoms, SPT) | 2014 | Spain | IgE | 45 | 88.400 | 20141122, Morales M
| | 5.2.1 - Source Exposed (Symptoms, SPT) | 2014 | Spain | IgE | 43 | 79.100 | 20141122, Morales M
| | 5.2.1 - Source Exposed (Symptoms, SPT) | 2014 | Spain | IgE | 33 | 83.900 | 20141122, Morales M
| | 5.2.1 - Source Exposed (Symptoms, SPT) | 2011 | Spain | IgE | 40 | 77.500 | 20110228, Boquete M
| | 5.2.1 - Source Exposed (Symptoms, SPT) | 2011 | Spain | IgE | 25 | 39.100 | 20110228, Boquete M
| | 5.2.1 - Source Exposed (Symptoms, SPT) | 2010 | Spain | IgE | 32 | 81.300 | 20100719, Iraola V
| | 5.2.2 - Source Exposed, Adults (Symptoms, SPT) | 1994 | Australia | IgE | 26 | 23.000 | | | 5.2.3 - Source Exposed, Children (Symptoms, SPT) | 1994 | Australia | IgE | 19 | 79.000 | 1994, OBrien RM
| | 5.2.3 - Source Exposed, Children (Symptoms, SPT) | 2003 | Malaysia | IgE | 40 | 87.500 | | | 5.2.5 - Source Exposed, Children (Symptoms, IgE) | 2006 | Australia | IgE | 77 | 74.300 | 20060524, Hales BJ
| | 5.3.1 - Source Exposed (Symptoms, IgE) | 2006 | Australia | IgE | 105 | 76.600 | 20060524, Hales BJ
| | 5.3.1 - Source Exposed (Symptoms, IgE) | 1996 | Australia | IgE | 35 | 96.000 | | | 5.3.1 - Source Exposed (Symptoms, IgE) | 2008 | Austria | IgE | 56 | 91.000 | 20081121, Weghofer M
| | 5.3.1 - Source Exposed (Symptoms, IgE) | 2012 | Belgium | IgE | 99 | 42.420 | 20110223, De Knop KJ
| | 5.3.1 - Source Exposed (Symptoms, IgE) | 2007 | Colombia | IgE | 90 | 64.400 | 20080220, Jimenez S
| | 5.3.1 - Source Exposed (Symptoms, IgE) | 2008 | France | IgE | 55 | 100.000 | 20081121, Weghofer M
| | 5.3.1 - Source Exposed (Symptoms, IgE) | 2008 | Italy | IgE | 67 | 90.000 | 20081121, Weghofer M
| | 5.3.1 - Source Exposed (Symptoms, IgE) | 1993 | Japan | IgE | 88 | 90.000 | 1993, Yasueda H
| | 5.3.1 - Source Exposed (Symptoms, IgE) | 2008 | Sweden | IgE | 65 | 85.000 | 20081121, Weghofer M
| | 5.3.1 - Source Exposed (Symptoms, IgE) | 2000 | Taiwan | IgE | 248 | 43.140 | 20000606, Hu C
| | 5.3.2 - Source Exposed (Symptoms, high IgE) | 2012 | France | IgE | 123 | 92.680 | 20120521, Bronnert M
| | 5.4.1 - Source Exposed (Symptoms, SPT, IgE) | 2012 | Australia | IgE | 37 | 65.000 | 20121018, Hales BJ
| | 5.4.1 - Source Exposed (Symptoms, SPT, IgE) | 2011 | Austria | IgE | 62 | 83.770 | 20110629, Resch Y
| | 5.4.1 - Source Exposed (Symptoms, SPT, IgE) | 2012 | France | IgE | 19 | 94.730 | 20120622, Casset A
| | 5.4.1 - Source Exposed (Symptoms, SPT, IgE) | 2012 | Italy | IgE | 26 | 96.150 | 20120622, Casset A
| | 5.4.1 - Source Exposed (Symptoms, SPT, IgE) | 2011 | Singapore | IgE | 225 | 63.000 | 20110221, Kidon MI
| | 5.4.1 - Source Exposed (Symptoms, SPT, IgE) | 2010 | Singapore | IgE | 30 | 83.300 | 20100326, Shek LP
| | 5.4.1 - Source Exposed (Symptoms, SPT, IgE) | 2010 | Singapore | IgE | 30 | 76.700 | 20100326, Shek LP
| | 5.4.1 - Source Exposed (Symptoms, SPT, IgE) | 2014 | Thailand | IgE | 96 | 72.000 | 20140530, Pulsawat P
| | 5.4.2 - Source Exposed (Symptoms, SPT, high IgE) | 2009 | Spain | IgE | 106 | 99.050 | 20090421, Asturias JA
| | 5.4.2 - Source Exposed (Symptoms, SPT, high IgE) | 2009 | Spain | SPT | 106 | 94.330 | 20090421, Asturias JA
| | 6.1 - General Population | 2003 | Barbados | IgE | 481 | 26.800 | | | 6.2 - General Population (Adults) | 2012 | Sweden | IgE | 371 | 1.080 | 20120528, Patelis A
|
|
Loading...
Der p 1
Homo sapiens
